Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 4,407 call options on the company. This is an increase of 246% compared to the average volume of 1,272 call options.
Institutional Trading of Microbot Medical
Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new stake in shares of Microbot Medical during the fourth quarter valued at approximately $118,000. Geode Capital Management LLC boosted its stake in shares of Microbot Medical by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after purchasing an additional 10,442 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Microbot Medical during the first quarter valued at approximately $57,000. Finally, Virtu Financial LLC purchased a new stake in shares of Microbot Medical during the first quarter valued at approximately $42,000. Hedge funds and other institutional investors own 16.30% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on MBOT shares. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 target price on shares of Microbot Medical in a research note on Thursday, April 10th. Wall Street Zen raised shares of Microbot Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th.
Read Our Latest Research Report on Microbot Medical
Microbot Medical Stock Performance
MBOT traded up $0.14 during midday trading on Thursday, hitting $2.64. The stock had a trading volume of 1,269,182 shares, compared to its average volume of 1,779,940. The company has a market cap of $96.04 million, a P/E ratio of -4.06 and a beta of 1.13. The business has a fifty day moving average of $2.55 and a 200 day moving average of $2.05. Microbot Medical has a 1 year low of $0.82 and a 1 year high of $3.38.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.07. On average, equities research analysts anticipate that Microbot Medical will post -0.71 earnings per share for the current year.
About Microbot Medical
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Read More
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.